UNS was spun out of United Biomedical Inc. (UBI) in 2014 led by UBI’s UB-311 program, an immunotherapeutic vaccine for the treatment of Alzheimer’s Disease. UNS intends to develop UB-311 as well as leverage UBI’s proprietary synthetic peptide platform technology to tackle other neurodegenerative disease indications such as Parkinson’s Disease and Huntington’s Disease. UNS is looking to rapidly advance candidates into clinical trials with goal of delivering breakthrough treatments to patients within the next 5-7 years and to become a leading global player in neurodegenerative diseases space.